Symrise stock: new clinical evidence, slightly lower pre-market
Published on 10/22/2026 at 08:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew evidence and upcoming dates
- At its October 21, 2026, release, Symrise presented new clinical findings and a joint Care & Wellness presence in the Americas.
- The next scheduled company update is the third-quarter 2026 interim statement on October 28, 2026.
- Symrise stock trades pre-market at EUR 100.16 at 8:39 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.83 percent below the Xetra close of October 21, 2026.
On October 21, 2026, Symrise presented new clinical evidence for skin and digestive health at SupplySide Global 2026, according to a Symrise release. The stock trades pre-market at EUR 100.16 at 8:39 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.83 percent below the Xetra close of October 21, 2026 (EUR 101.00).
Health research in Las Vegas
Symrise said its Care & Wellness Division would present Health Active Solutions and Probi together in the Americas for the first time. The release highlighted a randomized, placebo-controlled study of 108 women receiving 600 milligrams of Acerowell daily for 12 weeks, as well as an eight-week study involving 100 adults with occasional constipation. Symrise also presented the postbiotic Rham271h and additional digestive-health data for LP299V and LPGOS42. The company said the offerings would be shown at booth 2364 in Las Vegas.
Ahead of the Xetra open
The pre-market indication is EUR 0.84 below that reference. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Symrise stock.
Business and the next date
Symrise develops and supplies fragrances, flavorings, cosmetic ingredients and functional ingredients to customers in consumer, pharmaceutical, nutrition and pet-food markets. Its next scheduled company event is the Q3 2026 interim statement on October 28, 2026, according to the investor-relations calendar. Market context: Market report DAX.
